De Pardieu has advised the shareholders of TransAlpes on the sale of the TransCure bioServices group, CRO specializing in humanized mouse models, to Taconic Biosciences, world-leading provider of research models, and on their reinvestment within the Taconic group.
The acquisition further strengthens Taconic’s capabilities across oncology, immunology, infectious disease, inflammation, metabolic disease, and advanced modalities, providing researchers with the humanized systems essential for developing complex, mechanism-driven therapies.